<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04203784</url>
  </required_header>
  <id_info>
    <org_study_id>K 2019-9604</org_study_id>
    <nct_id>NCT04203784</nct_id>
  </id_info>
  <brief_title>Meropenem and Piperacillin Plasma Concentrations During CRRT</brief_title>
  <acronym>ABC2</acronym>
  <official_title>Meropenem and Piperacillin Plasma Concentrations During CRRT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study reports meropenem and piperacillin plasma concentrations in patients
      treated with either antibiotic and simultaneous continuous renal replacement therapy (CRRT).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2012</start_date>
  <completion_date type="Actual">December 31, 2016</completion_date>
  <primary_completion_date type="Actual">December 31, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma antibiotic concentrations at mid and end of dosing interval</measure>
    <time_frame>1 week</time_frame>
    <description>We vill report the measured plasma antibiotic concentrations at the mid and end of the dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma antibiotic concentrations at mid and end of dosing interval</measure>
    <time_frame>1 week</time_frame>
    <description>The percentage of patients having a concentration above the highest MIC (minimal inhibitory concentration) breakpoint for pathogens considered susceptible for the antibiotic.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relationships between plasma antibiotic concentrations and CRRT dose.</measure>
    <time_frame>1 week</time_frame>
    <description>We will report the correlation between measured plasma concentrations of either antibiotic and the intensity of the CRRT treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Influence of residual diuresis on the measured plasma antibiotic concentrations.</measure>
    <time_frame>1 week</time_frame>
    <description>We will report the correlation between measured plasma concentrations of either antibiotic and residual diuresis.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">135</enrollment>
  <condition>Sepsis</condition>
  <condition>Infection</condition>
  <condition>Antibiotic</condition>
  <condition>Renal Replacement Therapy</condition>
  <condition>Hemolysis</condition>
  <arm_group>
    <arm_group_label>Meropenem treated patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Piperacillin treated patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Plasma concentration measurements</intervention_name>
    <description>Plasma concentration measurements</description>
    <arm_group_label>Meropenem treated patients</arm_group_label>
    <arm_group_label>Piperacillin treated patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        ICU patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients treated in the study ICU and

          -  simultaneous CRRT and antibiotic treatment with either meropenem or
             piperacillin-tazobactam.

        Exclusion Criteria:

          -  none
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Karolinska University Hospital Solna</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 3, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2019</study_first_posted>
  <last_update_submitted>December 17, 2019</last_update_submitted>
  <last_update_submitted_qc>December 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Johan Petersson</investigator_full_name>
    <investigator_title>Senior ICU Consultant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemolysis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

